Skip to main content

Advertisement

Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

Fig. 4

Effects of osimertinib combined with pemetrexed or cisplatin on cell proliferation and cell death induction in PC9T790M cells. a PC9T790M cells were treated with 50 nM osimertinib, 50 nM pemetrexed or 500 nM cisplatin on the basis of the indicated schedules. After 12 days crystal violet assay was performed and absorbance was measured at 570 nm. Results are representative of three independent experiments. *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001 vs osimertinib; one-way analysis of variance followed by Bonferroni’s post-test. b PC9T790M cells were treated with drugs on the basis of the indicated schedules for up to 48 h. At the end of the treatment period cell death was quantified by fluorescence microscopy analysis on Hoechst 33342 and propidium iodide-stained cells. Results represent the mean ± standard deviation (SD) of three independent experiments. **p < 0.01, ***p < 0.001, ****p < 0.001 vs control; #p < 0.05 vs osimertinib; one-way analysis of variance followed by Bonferroni’s post-test

Back to article page